16.38
-0.53(-3.13%)
Currency In USD
| Previous Close | 16.91 |
| Open | 17.05 |
| Day High | 17.11 |
| Day Low | 16.3 |
| 52-Week High | 25.29 |
| 52-Week Low | 7.93 |
| Volume | 991,896 |
| Average Volume | 1.64M |
| Market Cap | 1.45B |
| PE | -5.89 |
| EPS | -2.78 |
| Moving Average 50 Days | 16.53 |
| Moving Average 200 Days | 17.95 |
| Change | -0.53 |
If you invested $1000 in Travere Therapeutics, Inc. (TVTX) 10 years ago, it would be worth $455.13 as of July 16, 2025 at a share price of $16.38. Whereas If you bought $1000 worth of Travere Therapeutics, Inc. (TVTX) shares 5 years ago, it would be worth $798.63 as of July 16, 2025 at a share price of $16.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
GlobeNewswire Inc.
Mar 17, 2025 11:01 AM GMT
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Add
Travere Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 9:30 PM GMT
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferencePres
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Feb 13, 2025 9:30 PM GMT
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets.